Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia .
Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.
The Office of Commercialization has awarded eight WSU researchers with the Commercialization Gap Fund (CGF). The CGF supports research projects with high market potential and provides researchers up to $50,000 to demonstrate their innovation(s) can m
New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM